drugset / Trial / NCT03733639

Tisseel® as a Reinforcement of Esophagojejunal Anastomoses

NCT03733639

Phase 4 Unknown 146 enrolled Germans Trias i Pujol Hospital
RandomizedParallel-groupSingle-blindPrevention

Summary

Background: The dehiscence of esophagojejunal anastomoses is one of the most serious complications after total gastrectomy in patients with gastric cancer. Any method of avoiding this problem will affect not only the postoperative course but also the prognostic of disease. Methods: This is a prospective, randomized and multicenter trial, within the Spanish EURECCA Esophagogastric Cancer Group, to investigate the efficacy of Tisseel® in reducing the rate of esophagojejunal anastomosis leakage in patients with gastric cancer. The rate of anastomosis leak will be measured with clinical, radiological and analytic parameters. Objective: Analyze the efficacy of Tisseel® as a reinforcement in reducing the rate of anastomotic esophagojejunal anastomoses.

Timeline

Start
2020-07-21
Primary completion
2021-07-01
Completion
2022-07-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fibrinogen Concentrate Human Protein / enzyme biologic